Tau Imaging: Use and Implementation in New Diagnostic and Therapeutic Paradigms for Alzheimer’s Disease DOI Creative Commons
Alexandra Gogola, Brian J. Lopresti, Davneet S. Minhas

и другие.

Geriatrics, Год журнала: 2025, Номер 10(1), С. 27 - 27

Опубликована: Фев. 14, 2025

Alzheimer's disease (AD) affects an estimated 6.9 million older adults in the United States and is projected to impact as many 13.8 people by 2060. As studies continue search for ways combat development progression of AD, it imperative ensure that confident diagnoses can be made before onset severe clinical symptoms new therapies evaluated effectively. Tau positron emission tomography (PET) has emerged one method may capable both, given its ability recognize presence tau, a primary pathologic hallmark AD; usefulness determining spatial distribution which necessary differentiating AD from other tauopathies; association with measures cognition. This review aims evaluate scope tau PET's utility trials practice. Firstly, potential using PET differential diagnoses, distinguishing dementias, considered. Next, value tool staging investigated. Finally, prognostic identifying individuals most at risk cognitive decline and, therefore, need of, likely benefit from, intervention, discussed.

Язык: Английский

Tau Imaging: Use and Implementation in New Diagnostic and Therapeutic Paradigms for Alzheimer’s Disease DOI Creative Commons
Alexandra Gogola, Brian J. Lopresti, Davneet S. Minhas

и другие.

Geriatrics, Год журнала: 2025, Номер 10(1), С. 27 - 27

Опубликована: Фев. 14, 2025

Alzheimer's disease (AD) affects an estimated 6.9 million older adults in the United States and is projected to impact as many 13.8 people by 2060. As studies continue search for ways combat development progression of AD, it imperative ensure that confident diagnoses can be made before onset severe clinical symptoms new therapies evaluated effectively. Tau positron emission tomography (PET) has emerged one method may capable both, given its ability recognize presence tau, a primary pathologic hallmark AD; usefulness determining spatial distribution which necessary differentiating AD from other tauopathies; association with measures cognition. This review aims evaluate scope tau PET's utility trials practice. Firstly, potential using PET differential diagnoses, distinguishing dementias, considered. Next, value tool staging investigated. Finally, prognostic identifying individuals most at risk cognitive decline and, therefore, need of, likely benefit from, intervention, discussed.

Язык: Английский

Процитировано

0